QuantumPharm Announces HK$1.13 Billion Placement to Fuel Expansion of AI-Driven R&D Platform

Jan 23, 2025 18:38 CST Updated 18:38

XtalPi

Computation-Driven Innovative Drug R&D Provider

On January 19, XtalPi announced that the company had entered into a placement agreement with the placing agent.

XtalPi Holdings Limited intends toHK$4.28 per shareApproximately 264 million shares were placed, raising HKD 1.13 billion. After deducting related costs and expenses, the net proceeds amounted to approximately HKD 1.125 billion (approximately RMB 1.05 billion).

This placement,CITIC Securities, Guotai Junan InternationalAs the Co-Overall Coordinator of XtalPi,KK Securities GroupAs its co-handling agent.

Hong Kong Stock Placement refers to the behavior of listed companies conducting refinancing by selling shares to specific investors.This behavior is similar to private placements in A-shares, but the review process and conditions are more relaxed.

The number of shares in this placement (assuming full subscription) accounts for approximately7.73%, representing approximately7.18%。

Before the placement, QuantumPharm Holdings held 6.51%, QuantumPharm Roc Holdings held 8.67%, Crete Heli held 3.6%, SeveningBAlpha held 2.57%, and Tencent held 12.89%, with a total shareholding of 34.24%.

After this placement, QuantumPharm Holdings holds 6.04%, QuantumPharm Roc Holdings holds 8.05%, Crete Heli holds 3.34%, SeveningBAlpha holds 2.39%, and Tencent holds 11.96%, with a total holding of 31.78%.

On June 13, 2024, XtalPi officially listed on the Main Board of the Hong Kong Stock Exchange, becoming the first company to go public under Chapter 18C of the HKEX's Specialized Technology Companies regime.

The company leverages quantum physics, artificial intelligence, and robotic automation technologies to provide integrated R&D solutions for multiple industries, including pharmaceuticals, biotechnology, agrotechnology, energy, and novel chemicals.

XtalPi's offering price was HK$5.28 per share, with 187 million shares issued, raising a total of HK$1.138 billion. After deducting issuance expenses, the net proceeds amounted to HK$1.043 billion.

Recommended Reading